Salvage Therapy Including Foscarnet and Ibalizumab for Multidrug-Resistant Human Immunodeficiency Virus Type 2 Infection

Clin Infect Dis. 2024 Apr 10;78(4):1005-1010. doi: 10.1093/cid/ciad695.

Abstract

We evaluated Ibalizumab (IBA)-containing standardized optimized salvage regimen (with or without a 4-week foscarnet induction) in individuals harboring multidrug-resistant human immunodeficiency virus type 2 (HIV-2). Nine were included; 2 achieved virological suppression after foscarnet induction with a sustained suppression at Week 24 after IBA initiation, and an additional individual at Week 24 after Ibalizumab initiation.

Keywords: HIV-2; foscarnet; ibalizumab; multi-drug resistance; salvage therapy.

MeSH terms

  • Anti-HIV Agents* / therapeutic use
  • Antibodies, Monoclonal*
  • Foscarnet / therapeutic use
  • HIV Infections* / drug therapy
  • HIV-2
  • Humans
  • Salvage Therapy

Substances

  • Foscarnet
  • ibalizumab
  • Anti-HIV Agents
  • Antibodies, Monoclonal